Drug Price Transparency
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with several other Democratic senators, yesterday introduced bills aimed at increasing transparency for prescription drug prices and reducing costs for Medicare Part D enrollees.
The Department of Health and Human Services’ Office of Inspector General yesterday proposed excluding from safe harbor protection under the Anti-Kickback Statute rebates paid by prescription drug makers to pharmacy benefit managers, Medicare Part D plans and Medicaid managed care organizations.
Rising drug prices – as well as shortages for many critical medicines – are hurting patients and the hospitals and health systems that care for them each day.
Drug spending is rising dramatically on top of historic growth. High drug prices create real challenges for hospitals and the patients they treat.
The American Hospital Association (AHA), the Federation of American Hospitals (FAH), and the American Society of Health-System Pharmacists (ASHP) released a new report finding that continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and…
The AHA today voiced support for a Centers for Medicare & Medicaid Services’ proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to “rein in skyrocketing drug prices” for patients and the providers who serve them.
The AHA voiced support for a Centers for Medicare & Medicaid Services’ proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to “rein in skyrocketing drug prices” for patients and the providers who serve them. “We appreciate CMS’…
The Centers for Medicare & Medicaid Services today issued a proposed rule aimed at increasing drug price transparency and reducing the price of prescription drugs and biological products to consumers by requiring drug manufacturers to include list prices in all direct-to-consumer television…
The House of Representatives yesterday passed two bills that would prohibit health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance.